Aidoc vs Atomwise

Both companies have comparable valuations.

Aidoc raised $370M while Atomwise raised $219M.

Aidoc has the higher Awaira Score of 67.

Aidoc: Aidoc is an Israeli artificial intelligence company founded in 2016 that develops clinical decision support software for radiology and medical imaging. The platform uses deep learning algorithms to analyze medical images, prioritize critical findings, and alert radiologists to potential abnormalities, particularly focusing on conditions requiring urgent intervention. Aidoc's core offering integrates into existing hospital workflows and PACS systems, enabling radiologists to identify and triage high-risk cases more efficiently. The company operates in the clinical AI segment, competing with firms like Zebra Medical Vision and Enlitic in automated imaging analysis. Aidoc's technology addresses the growing bottleneck of radiologist workload and diagnostic delays by automating preliminary image screening and flagging priority cases. The platform reportedly covers multiple pathologies including stroke, pulmonary embolism, and other acute conditions. As of the latest available data, Aidoc has secured $370 million in total funding through Series D stage, though its valuation remains not disclosed. The company has expanded internationally and serves healthcare institutions across multiple regions. Aidoc's growth trajectory reflects increasing institutional adoption of AI-assisted diagnostic tools in radiology departments globally, driven by workforce shortages and demand for faster diagnostic turnaround times in clinical settings. Aidoc focuses on clinical workflow integration rather than replacement, embedding AI directly into existing radiology infrastructure to accelerate diagnostic processes.. Atomwise: Atomwise is an artificial intelligence company focused on drug discovery and development, founded in 2012 and headquartered in the United States. The company uses AI and computational chemistry to identify and optimize potential drug candidates, reducing the time and cost associated with traditional pharmaceutical research methods. Atomwise's platform leverages machine learning algorithms to screen vast chemical libraries and predict molecular interactions, enabling faster identification of promising compounds for various therapeutic areas including oncology, infectious diseases, and genetic disorders. The company has secured $219 million in total funding and operates at the Series B stage, though its current valuation remains undisclosed. Atomwise's approach combines physics-based molecular modeling with machine learning to simulate how potential drugs interact with disease targets. The platform has been applied to multiple drug discovery projects across both internal programs and partnerships with pharmaceutical companies and research institutions. Atomwise competes in the growing computational drug discovery sector alongside companies utilizing AI for pharmaceutical development. The company's technology addresses significant pain points in drug development, including extended timelines and high failure rates. Its trajectory reflects the increasing adoption of AI-driven approaches in healthcare and pharmaceutical industries, positioning it within a broader trend toward computational acceleration of biomedical research and development processes. Atomwise applies physics-informed machine learning to molecular simulation for drug discovery, combining computational chemistry with AI to accelerate preclinical pharmaceutical development..

Atomwise was founded first in 2012. Aidoc was founded in 2016.